Symons Capital Management Inc. lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 8.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,629 shares of the biopharmaceutical company’s stock after selling 4,606 shares during the period. Celgene makes up about 2.2% of Symons Capital Management Inc.’s investment portfolio, making the stock its 25th largest position. Symons Capital Management Inc.’s holdings in Celgene were worth $4,729,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of CELG. First PREMIER Bank acquired a new position in Celgene in the third quarter worth $26,000. Liberty Wealth Management LLC boosted its holdings in Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares during the period. B & T Capital Management DBA Alpha Capital Management acquired a new position in Celgene in the third quarter worth $28,000. Massey Quick Simon & CO. LLC acquired a new position in shares of Celgene during the second quarter valued at $33,000. Finally, Lenox Wealth Advisors LLC acquired a new position in shares of Celgene during the third quarter valued at $37,000. Institutional investors own 72.31% of the company’s stock.
Several equities analysts have recently issued reports on CELG shares. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. BidaskClub raised shares of Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Wells Fargo & Co set a $110.00 price target on shares of Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Standpoint Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Robert W. Baird cut shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective on the stock. in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $97.31.
In related news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.39% of the company’s stock.
Celgene stock traded up $0.54 during midday trading on Friday, hitting $109.54. The company’s stock had a trading volume of 5,706,800 shares, compared to its average volume of 6,764,924. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $109.75. The stock’s 50-day moving average price is $102.54 and its 200-day moving average price is $96.76. The company has a market capitalization of $76.64 billion, a PE ratio of 14.39, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.70 by $0.29. The company had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. As a group, equities analysts anticipate that Celgene Co. will post 10.7 EPS for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What is a Candlestick Chart?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.